A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

Trial Profile

A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Interstitial lung diseases; Systemic scleroderma
  • Focus Registrational; Therapeutic Use
  • Acronyms SENSCIS
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 29 Jun 2017 Trial design published in the Clinical and Experimental Rheumatology
    • 16 Dec 2016 Planned End Date changed from 1 May 2018 to 1 Dec 2018.
    • 16 Dec 2016 Planned primary completion date changed from 1 Apr 2018 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top